myTomorrows Enhances Clinical Trial Search with ISRCTN Registry for Better Patient Access

myTomorrows Enhances Clinical Trial Search with ISRCTN Registry

In a significant move to expand access to clinical trials, myTomorrows, a global health technology company, has recently incorporated the ISRCTN registry into its platform. The aim is to provide healthcare professionals with a more comprehensive resource for identifying clinical trials and Expanded Access Programs available to their patients. This upgrade sets myTomorrows apart as a leading source for connecting patients with various pre-approval treatment options.

The addition of the ISRCTN registry allows myTomorrows to tap into a broader array of trusted, World Health Organization-endorsed public registries such as clinicaltrials.gov and EudraCT. This enhancement means that healthcare professionals can now access one of the most extensive and unbiased search platforms globally, covering clinical trials in various countries, including the UK. Particularly after Brexit, the ISRCTN registry has emerged as an essential tool for healthcare providers working with UK-centric studies, including non-commercial research funded by the National Institute for Health Research (NIHR).

By integrating the ISRCTN registry, myTomorrows enables healthcare professionals to easily pinpoint clinical trials registered solely on this platform, ensuring that they have all relevant and localized data at their fingertips. This improvement significantly reduces the time spent on searching through multiple sources from hours down to minutes, thereby enhancing the capability of healthcare professionals to stay informed about trials that may benefit their patients.

Further enhancing the user experience, myTomorrows has introduced various usability improvements, including an integrated AI assistant that pre-screens and matches unique patient medical profiles with trial eligibility criteria. The implementation of this technology cuts down search and pre-screening time by an impressive 90%, allowing healthcare professionals to focus more on patient care rather than on administrative tasks.

Moreover, the platform has expanded its functionality to support multi-country searches across continental Europe and automatically checks for related diseases. This new feature enables healthcare providers to uncover trials not just for the illness at hand, but also for associated health issues, thereby broadening the potential treatment avenues for patients.

Once relevant trials are identified, the myTomorrows platform facilitates secure referrals to trial sites while ensuring compliance with GDPR and ISO standards. Healthcare professionals can also connect directly with trial sites, further streamlining the referral process and enhancing communication.

In addition to the new search capabilities, myTomorrows stands out by providing information on the latest clinical research findings related to ongoing developmental treatments. This feature summarizes critical information, including a drug's mechanism, efficacy, and safety profile related to clinical trials, empowering healthcare professionals to make informed decisions about which trials may be most suitable for their patients more rapidly.

According to Michel van Harten, MD, the CEO of myTomorrows, this platform is a groundbreaking discovery tool for healthcare professionals looking to gain a comprehensive understanding of clinical trials across the UK, USA, and EU. He emphasized that the latest updates directly cater to the needs of healthcare professionals, who require a reliable and centralized source of information to streamline patient referrals, bridge information gaps, and facilitate informed decision-making.

With an impressive track record, myTomorrows has assisted over 14,000 patients and 2,100 healthcare professionals worldwide in discovering and navigating pre-approval treatment options. Its ICO-registered, ISO27001, and GDPR-compliant technology effectively conducts detailed searches across multiple trusted clinical trial registries, ensuring seamless access for healthcare providers in identifying suitable trials beyond their usual reach.

In conclusion, the integration of the ISRCTN registry and the introduction of advanced AI capabilities mark a new chapter for myTomorrows as it continues to enhance the platform based on feedback from healthcare professionals. This innovation is pivotal not only in saving valuable time for physicians but also in significantly improving patient access to potentially life-saving investigational treatments, thus fulfilling its commitment to breaking down barriers in treatment access.

About myTomorrows

myTomorrows is dedicated to connecting patients with vital treatment options by leveraging innovative technology that enables comprehensive searches of clinical trial databases. With its headquarters in Amsterdam and an office in New York City, myTomorrows remains committed to supporting healthcare professionals and patients alike in navigating the complexities of treatment availability.